Arrowstreet Capital
WHWK

Arrowstreet Capital’s Whitehawk Therapeutics WHWK Stock Holding History

Arrowstreet Capital’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,382
Closed -$35K – 2586
2020
Q4 		$35K Hold
2,382
– – ﹤0.01% 2244
2020
Q3 		$54K Buy
+2,382
New +$50.1K ﹤0.01% 2281

Other funds holding WHWK

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SAM
Scion Asset Management Saratoga, California $1.38B AUM 43.96% 1-Year Est. Return

Arrowstreet Capital's WHWK Position: Q1 2021 in Review

Arrowstreet Capital sold out of Whitehawk Therapeutics (WHWK) in Q1 2021, closing a stake of 2,382 shares — an estimated $35K sold.

Arrowstreet Capital first reported a position in WHWK in Q3 2020 and held it in 2 quarters. The position peaked at $54K in Q3 2020. 42 funds tracked by Wall St. Rank hold WHWK as of Q1 2021.

  • Arrowstreet Capital reported no remaining Whitehawk Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Arrowstreet Capital sold 2,382 Whitehawk Therapeutics shares in Q1 2021, an estimated $35K.
  • Arrowstreet Capital first reported a position in Whitehawk Therapeutics in Q3 2020 and held it in 2 quarters.
  • Arrowstreet Capital's Whitehawk Therapeutics position peaked at $54K in Q3 2020.
  • 42 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2021.

Based on Arrowstreet Capital's 13F filing for Q1 2021, filed 14 May 2021.